In the mid-20th century, the American pharmaceutical industry transformed rapidly, evolving from a nascent field into a global leader in drug discovery and development. This evolution was shaped by a convergence of early patent medicines and research science, bolstered by wartime necessity and government investment, ultimately creating a model that reshaped medicine and generated enormous wealth.
In his recent book, historian Barry Werth chronicles this transformation, highlighting the industry’s roots in a time when effective treatments were scarce. According to a Harvard Medical School alumnus from the 1930s, medical education then largely neglected disease treatment, focusing instead on palliative care such as sedation and pain relief. Early 20th-century drug research was dominated by German chemists; one notable breakthrough was Salvarsan, introduced in 1910 by biochemist Paul Ehrlich. Salvarsan, a synthetic arsenic-based compound, was the first “magic bullet” aimed at treating syphilis and was developed through empirical testing of coal-tar-based dyes against microbes.
The ascendancy of the U.S. pharmaceutical sector accelerated during World War II. The war disrupted German drug development due to Nazi policies that dismissed animal testing and targeted Jewish scientists, thus creating a gap that American firms filled. Central to this shift was Vannevar Bush, an electrical engineer who oversaw U.S. wartime research and development. Rather than establishing state-run laboratories, Bush pioneered a system of government contracts that directed public funds to private companies and universities, fostering innovation within a market-based framework. This approach, previously applied primarily to aeronautics, proved effective in pharmaceutical research.
American companies mastered the mass production of penicillin, a critical factor in reducing Allied casualties during the D-Day invasion. Postwar, these firms expanded their drug discovery efforts, producing antibiotics, cortisone, and early treatments for hypertension. The financial success of pharmaceutical manufacturing became evident as it emerged as one of the most profitable sectors in the U.S. economy by the 1950s. However, these profits drew scrutiny from Congress, leading to hearings in 1959 over high markups, including a case where Schering sold the hormone estradiol at prices exceeding 7,000 percent of production cost. Senator Estes Kefauver condemned such profit levels as “immoral,” sparking debates over the balance between industry earnings and public health interests.
Pharmaceutical companies defended their margins, stating they were necessary to fund costly research, while critics pointed out the disproportionate spending on marketing compared to research and development. The American Medical Association aligned with the industry, relying on advertising revenues to oppose moves toward nationalized healthcare. Legislative attempts to regulate the industry culminated in a 1962 law requiring new drugs to demonstrate efficacy in addition to safety. However, this bill stopped short of limiting patents or profits, and arguably increased the cost and complexity of developing new drugs, prompting firms to aggressively protect their intellectual property.
Werth’s narrative underscores the significant benefits that have come from the industry’s innovations, suggesting early government efforts to regulate pharmaceutical profits may have unintentionally intensified challenges for both companies and consumers. Nonetheless, studies show that other nations with stricter drug price controls, such as the United Kingdom and Switzerland, have achieved comparable pharmaceutical innovation without the high profit margins seen in the U.S.
As debates over the pharmaceutical industry continue, reflecting on these historical developments offers valuable context for policymakers and public stakeholders. While the American model has yielded groundbreaking treatments, evidence suggests that balancing profit regulation and innovation remains a complex but achievable goal.